AstraZeneca and The Medicines Company announce global collaboration in acute ischaemic heart disease

Wednesday, 25 April 2012

Global Development and Commercialisation Agreement to Begin with Co-Promotion of BRILINTA (ticagrelor) in United States

AstraZeneca and The Medicines Company today announced a global collaboration for their acute ischaemic heart disease compounds. The first part of this collaboration is a US co-promotion for AstraZeneca’s oral antiplatelet medicine BRILINTA. Under the terms of the co-promotion agreement, The Medicines Company sales force will begin supporting BRILINTA in May 2012. This will complement the AstraZeneca sales team’s promotion of BRILINTA to US hospital customers and practitioners whose patients with acute coronary syndrome (ACS) may benefit from this important therapy.

“The Medicines Company is a respected organisation with a strong network in interventional cardiology," said Lisa Schoenberg, Vice President, US Sales and Marketing, Growth Portfolio, AstraZeneca. “We have laid the groundwork for BRILINTA in the US with strong managed market access as well as hospital formulary and protocol access such that now is the right time to bring this important medicine to more patients with ACS through additional support in the acute setting.”

Under the terms of the global collaboration, a joint development committee and a joint commercialisation committee have been established to prepare and deliver global development and commercialisation plans related to AstraZeneca’s BRILINTA and The Medicines Company’s Angiomax (bivalirudin) for injection and cangrelor, which is in development as an acute intravenous antiplatelet agent. Implementation of these plans is subject to further agreements between both parties.

The agreement also outlines terms for the four-year US BRILINTA co-promotion agreement in which AstraZeneca will pay The Medicines Company $15 million per year for performing pre-agreed commercialisation activities with up to an additional $5 million per year paid if performance thresholds are met.

“Our goal in joining this global collaboration with AstraZeneca is to help improve patient care with a comprehensive suite of solutions for acute ischaemic heart disease,” said Brent Furse, Senior Vice President and Chief Customer Officer of The Medicines Company. “This opportunity aligns with our vision to lead in acute, intensive care hospital medicine globally.”



BRILINTA is an oral antiplatelet treatment for ACS. BRILINTA is a direct-acting P2Y12 receptor antagonist in a new chemical class called cyclopentyltriazolopyrimidines (CPTPs).

BRILINTA is approved in 73 countries, including in the European Union under the trade name BRILIQUE and in the US, Brazil, Canada, Australia and Russia, under the trade name BRILINTA.

BRILINTA and BRILIQUE are trademarks of the AstraZeneca group of companies.

About Acute Coronary Syndrome (ACS)

ACS is an umbrella term for conditions that result from insufficient blood supply to the heart muscle. These conditions range from unstable angina (UA), non–ST-elevation myocardial infarction (NSTEMI), or ST-elevation myocardial infarction (STEMI).

About Angiomax (bivalirudin) for injection

Angiomax is a direct thrombin inhibitor with a naturally reversible mechanism of action and a 25 minute half-life. In the United States, Angiomax with provisional use of glycoprotein IIB/IIIA (GPI) is indicated in patients undergoing angioplasty, also called percutaneous coronary intervention (PCI), and in patients with, or at risk of, heparin-induced thrombocytopenia (HIT) or heparin-induced thrombocytopenia and thrombosis syndrome (HIT/HITTS) undergoing PCI. In addition, Angiomax is indicated for use as an anticoagulant in patients with unstable angina (UA) undergoing percutaneous transluminal coronary angioplasty (PTCA). Angiomax is intended for use with aspirin. Angiomax is not approved for use in ACS patients not undergoing PCI or PTCA.

About Cangrelor

Cangrelor is an investigational intravenous small molecule antiplatelet agent not approved for commercial use in any market. Cangrelor was exclusively licensed in December 2003 by The Medicines Company from AstraZeneca.

About AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialisation of prescription medicines for gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit:

About The Medicines Company

The Medicines Company provides medical solutions to improve health outcomes for patients in acute and intensive care hospitals worldwide. These solutions comprise medicines and knowledge that directly impact the survival and well-being of critically ill patients.


AstraZeneca Media Enquiries UK

Esra Erkal-Paler +44 20 7604 8030
Sarah Lindgreen +44 20 7604 8033

AstraZeneca Media Enquiries US

Stephanie Jacobson +1 302 885 5924 mob: +1 302 379 0443
Julia Walker +1 302 885 5172 mob: +1 610 350 8240

Investor Enquiries UK

James Ward-Lilley +44 20 7604 8122 mob: +44 7785 432613
Karl Hård +44 20 7604 8123 mob: +44 7789 654364
Nicklas Westerholm +44 20 7604 8124 mob: +44 7585 404950

Investor Enquiries US

Ed Seage +1 302 886 4065 mob: +1 302 373 1361
Jorgen Winroth +1 212 579 0506 mob: +1 917 612 4043

The Medicines Company Enquiries

Michael Mitchell +1 973 290 6097 (US)


  • Corporate and financial
  • Science